PUBLIC COMPANY
save$BIIBBIOGEN INC.
$BIIB219.88-1.32%Cambridge, MA, USupdated 21h ago
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fum read more
…
community read0 votes
pipeline
13
marketed
5
phase 3
3
catalysts ytd
7
approvals ytd
1
recalls ytd
0
Pipeline(13)
view full pipeline →pipeline depth13 products
2Phase 11Phase 23Phase 35Marketed1Discontinued1Unknown
Marketed
diroximel fumarate DR
Relapsing Remitting Multiple Sclerosis (RRMS)
Marketednatalizumab
Crohn's Disease (Regional Enteritis)
Marketednusinersen
Spinal Muscular Atrophy (SMA)
Marketedpeginterferon beta-1a
Progressive Relapsing Multiple Sclerosis (PRMS)
Marketedtofersen sodium
Amyotrophic Lateral Sclerosis
Phase 3felzartamab
Membranous Glomerulonephritis
Phase 3litifilimab
Cutaneous Lupus Erythematosus
C-type lectin domain family 4 member C
Phase 3salanersen
Spinal Muscular Atrophy (SMA)
Phase 2diranersen
Alzheimer's Disease
Phase 1BIIB-142
Lupus Nephritis
Phase 1izastobart
Solid Tumor
DiscontinuedAduhelm
Alzheimer's disease (withdrawn from market 2024)
Upcoming
Recent(90d)
earnings (2)
🐶 Hiring Signal
next earnings Oct 28, 2026
Where BIOGEN INC. is staffing up — a leading indicator of pipeline and commercial priorities.
News
no news has mentioned this company yet
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that